Cypilos (Testosterone Cypionate)

About the Product

Cypilos is a research compound from Driada Medical, presented as a solution for intramuscular injection containing Testosterone Cypionate 250mg/mL. Testosterone Cypionate is an oil-soluble ester prodrug of the endogenous androgen hormone, testosterone . The cypionate ester is a long-chain fatty acid that slows the release of the active hormone into the bloodstream following administration, resulting in a sustained half-life of approximately eight days .

The product is intended for laboratory research use only and features an integrated QR code on the packaging for detailed product verification. Its chemical formula is C₂₇H₄₀O₃, with a molecular weight of 412.61 g/mol .

• Product Name: Cypilos (Testosterone Cypionate 250mg/mL)

• Brand: Driada Medical

• Form: Injectable solution (oil-based)

• For Research Use Only.

Research Applications & Mechanism of Action

• Androgen Receptor Agonist: Testosterone Cypionate functions as a potent agonist at the androgen receptor (AR). Upon administration, the cypionate ester is cleaved, releasing active testosterone which binds to ARs in target tissues . This binding initiates a signaling cascade that regulates gene transcription and cellular changes related to androgenic activity .

• Protein Anabolism: By activating the androgen receptor, testosterone promotes protein anabolism (building up of proteins) and reduces protein catabolism (breakdown), which can be studied in models of muscle physiology and metabolic research .

• Erythropoiesis: Testosterone has been shown to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulation factor, a relevant area for hematological research .

• Lipid and Glucose Metabolism: Testosterone plays a significant role in systemic metabolism. Research applications can include studying its effects on lipid profiles and glucose homeostasis .

Research & Scientific Background

• Clinical Context: Testosterone cypionate is a well-characterized compound with an established history in the clinical management of male hypogonadism. Indications for testosterone replacement therapy include primary hypogonadism (testicular failure) and hypogonadotropic hypogonadism (pituitary/hypothalamic dysfunction) .

• Pharmacokinetics: The compound is designed for slow, sustained absorption when administered in an oil vehicle. It exhibits a half-life of approximately 8 days and is metabolized primarily in the liver, with about 90% of a dose excreted in urine as conjugates .

• Research on Genetic Variability: A research article identified on this topic studied the impact of the UGT2B17 gene polymorphism on the steroid profile of athletes following testosterone cypionate administration. The study demonstrated that genetic differences in this enzyme can influence how the body metabolizes and eliminates exogenous testosterone, which has significant implications for research into personalized medicine and the detection of exogenous hormone administration .